KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Novartis Ag (NVS) Non-Current Receivables (2017 - 2025)

Novartis Ag's Non-Current Receivables history spans 9 years, with the latest figure at $403.0 million for Q4 2025.

  • On a quarterly basis, Non-Current Receivables rose 125.14% to $403.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $403.0 million, a 125.14% increase, with the full-year FY2025 number at $403.0 million, up 125.14% from a year prior.
  • Non-Current Receivables hit $403.0 million in Q4 2025 for Novartis Ag, up from $179.0 million in the prior quarter.
  • Over the last five years, Non-Current Receivables for NVS hit a ceiling of $403.0 million in Q4 2025 and a floor of $179.0 million in Q4 2024.
  • Historically, Non-Current Receivables has averaged $235.4 million across 5 years, with a median of $197.0 million in 2022.
  • Biggest five-year swings in Non-Current Receivables: dropped 16.36% in 2024 and later skyrocketed 125.14% in 2025.
  • Tracing NVS's Non-Current Receivables over 5 years: stood at $184.0 million in 2021, then grew by 7.07% to $197.0 million in 2022, then increased by 8.63% to $214.0 million in 2023, then decreased by 16.36% to $179.0 million in 2024, then skyrocketed by 125.14% to $403.0 million in 2025.
  • Business Quant data shows Non-Current Receivables for NVS at $403.0 million in Q4 2025, $179.0 million in Q4 2024, and $214.0 million in Q4 2023.